Table 1.
Main characteristics of patients, treatment, and outcome.
| Male, 72 years old CLL, A0, del13q/ HCL Previously treated |
Male, 75 years old CLL, A0, trisomy 12 Never treated |
Male, 80 years old SLL/CLL, del13q Previously treated |
Male, 75 years old CLL, AI, del11q, del13q Never treated |
|
|---|---|---|---|---|
| Comorbidity | Malignant melanoma and basal cell carcinoma of the skin (surgical treatment) | Sleep apnea, diverticulitis | Squamous carcinoma in tonsillar fossa. Treated with cetuximab and radiotherapy in 2017 | Coronary heart disease, hypertension, basal cell carcinoma of the skin |
| Symptoms |
Fever (24 h) and diarrhea (4 days). No respiratory symptoms, SpO2: 96% |
Fever and malaise (7 days). No respiratory symptoms, SpO2: 96% |
Fever and dry cough (24 h). Slight shortness of breath, SpO2: 95% |
Fever and dry cough (24 h). SpO2: 98% |
|
Chest X-ray/ CT scan |
Slight lower right lung infiltrate | Upper left lung infiltrate | Bilateral interstitial infiltrate | Bilateral interstitial infiltrate |
| WBC (×109/L) | 3.5 | 16.95 | 2.4 | 56.9 |
| ALC (×109/L) | 0.35 | 13 | 0.3 | 50.1 |
| Hb (g/L) | 138 | 139 | 131 | 119 |
| Platelets (×109/L) | 76 | 77 | 163 | 163 |
| CRP (mg/dL) (N <1) | 4.8 | 0.4 | 16 | 7.7 |
| Procalcitonin (ng/ml) (N < 0.5) | 0.48 | 0.05 | 0.07 | 0.57 |
| LDH (U/L) (N < 234) | 282 | 232 | 304 | 199 |
| Ferritin (ng/mL) (N < 400) | 776 | 487 | 997 | 167 |
| D-Dimer (ng/mL) (N < 500) | 500 | 900 | 400 | 300 |
| Troponin I (ng/L) (N < 45) | 3.0 | 4.9 | 6.3 | 7.7 |
| Treatment |
Lopinavir/ritonavir oral (4 days) Hydroxychloroquine oral (4 days) Azithromycin (4 days) |
Lopinavir/ritonavir oral (7 days) Hydroxychloroquine oral (5 days) Azithromycin oral (5 days) |
Ceftriaxone iv (4 days) Teicoplanin iv (4 days) Lopinavir/ritonavir oral (7 days) Hydroxychloroquine oral (5 days) Azithromycin oral (5 days) |
Ceftriaxone iv (2 days) Teicoplanin iv (2 days) Lopinavir/ritonavir oral (2 days) Hydroxychloroquine oral (2 days) Azithromycin oral (2 days) |
| Outcome | Recovery. Referred (day 4) to ambulatory care program | Recovery. Referred (day 8) to ambulatory care program | Recovery. Referred (day 8) to ambulatory care program | Recovery. Referred (day 24) to ambulatory care program |
COVID-19 preventive measures as per the Spanish Health System and Ad hoc Hospital Clinic of Barcelona Recommendations. Diagnosis by RT-PCR.
ALC absolute blood lymphocyte count, CR complete response, HCL hairy-cell leukemia, PR partial response.